Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions

Clinical Biochemistry

Volumn 45, Issue 3, 2012, Pages 237-242

  Karatolios, Konstantinos ^a   Pankuweit, Sabine ^a   Goettsch, Claudia ^b   Hofbauer, Lorenz C ^b   Timmesfeld, Nina ^a   Al Fakhri, Nadia ^a   Maisch, Bernhard ^a   Schoppet, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Biomarkers; Osteoprotegerin; Pericardial effusion; TNF related apoptosis inducing ligand

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

DEMOGRAPHY; FEMALE; HUMANS; LEUKOCYTE COUNT; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OSTEOPROTEGERIN; PERICARDIAL EFFUSION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84856468886     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.12.003     Document Type: Article

References (30)

1. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
2. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and Osteoprotegerin. Circ Res 2004, 95:1046-1057.
3. Walsh M.C., Kim N., Kadono Y., Rho J., Lee S.Y., Lorenzo J., et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006, 24:33-63.
4. Leibbrandt A., Penninger J.M. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008, 1143:123-150.
5. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
6. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
7. Vitovski S., Phillips J.S., Sayers J., Croucher P.I. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007, 282:31601-31609.
8. Wiezorek J., Holland P., Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010, 16:1701-1708.
9. Kavurma M.M., Schoppet M., Bobryshev Y.V., Khachigian L.M., Bennett M.R. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem 2008, 283:7754-7762.
10. Maisch B., Seferović P.M., Ristić A.D., Erbel R., Rienmüller R., Adler Y., et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004, 25:587-610.
11. Maisch B., Ristić A.D., Pankuweit S. Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J 2002, 23:1503-1508.
12. Schoppet M., Sattler A.M., Schaefer J.R., Herzum M., Maisch B., Hofbauer L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003, 88:1024-1028.
13. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
14. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
15. Mori K., Ikari Y., Jono S., Shioi A., Ishimura E., Emoto M., et al. Association of serum TRAIL level with coronary artery disease. Thromb Res 2010, 125:322-325.
16. Schoppet M., Sattler A.M., Schaefer J.R., Hofbauer L.C. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006, 184:446-447.
17. Soós P., Juhász-Nagy A., Ruskoaho H., Hartyánszky I., Merkely B., Tóth M., et al. Locally different role of atrial natriuretic peptide (ANP) in the pericardial fluid. Life Sci 2002, 71:2563-2573.
18. Schoppet M., Ruppert V., Hofbauer L.C., Henser S., Al-Fakhri N., Christ M., et al. TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochem Biophys Res Commun 2005, 338:1745-1750.
19. Burgess L.J. Biochemical analysis of pleural, peritoneal and pericardial effusions. Clin Chim Acta 2004, 343:61-84.
20. Ojeda W., Martínez-Toro J.A. Diagnosis and management of pericardial effusions. P R Health Sci J 2006, 25:255-258.
21. Szturmowicz M., Tomkowski W., Fijalkowska A., Burakowski J., Sakowicz A., Filipecki S. The role of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) evaluation in pericardial fluid for the recognition of malignant pericarditis. Int J Biol Markers 1997, 12:96-101.
22. Szturmowicz M., Tomkowski W., Fijalkowska A., Kupis W., Cieślik A., Demkow U., et al. Diagnostic utility of CYFRA 21-1 and CEA assays in pericardial fluid for the recognition of neoplastic pericarditis. Int J Biol Markers 2005, 20:43-49.
23. Koh K.K., Kim E.J., Cho C.H., Choi M.J., Cho S.K., Kim S.S., et al. Adenosine deaminase and carcinoembryonic antigen in pericardial effusion diagnosis, especially in suspected tuberculous pericarditis. Circulation 1994, 89:2728-2735.
24. Brown J.M., Vessella R.L., Kostenuik P.J., Dunstan C.R., Lange P.H., Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001, 7:2977-2983.
25. Seidel C., Hjertner Ø., Abildgaard N., Heickendorff L., Hjorth M., Westin J., et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001, 98:2269-2271.
26. Lipton A., Ali S.M., Leitzel K., Chinchilli V., Witters L., Engle L., et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002, 8:2306-2310.
27. Yun T.J., Chaudhary P.M., Shu G.L., Frazer J.K., Ewings M.K., Schwartz S.M., et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998, 161:6113-6121.
28. Sato K., Niessner A., Kopecky S.L., Frye R.L., Goronzy J.J., Weyand C.M. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006, 203:239-250.
29. Fiumara P., Snell V., Li Y., Mukhopadhyay A., Younes M., Gillenwater A.M., et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001, 98:2784-2790.
30. Pettersen I., Bakkelund W., Smedsrød B., Sveinbjørnsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res 2005, 25:3809-3816.